Catalent Pharma Solutions reports on its supply pact with InterveXion, a Little Rock, Arkansas-headquartered clinical-stage biopharmaceutical company, to support the production of IXT-m200, InterveXion’s investigational anti-methamphetamine antibody.

Catalent has supported InterveXion by engineering the cell line that expresses the drug’s antibody with Catalent’s proprietary GPEx technology, a cell-line technology, to complete process development. Catalent provided cGMP manufacturing for the clinical trial at the company’s biomanufacturing facility in Madison, Wisconsin.

InterveXion has enrolled the first patient in a Phase IIa, parallel-group, placebo-controlled, double-blind study of the effect of IXT-m200 on methamphetamine pharmacokinetics and subjective effects in methamphetamine users. IXT-m200, a monoclonal antibody that specifically binds methamphetamine in the blood, is being studied as a pharmacological treatment for use in conjunction with behavioral therapies by altering methamphetamine pharmacokinetics in human subjects to result in reduced or blocked subjective effects that reinforce methamphetamine use.

Source: Catalent Pharma Solutions